Vir Biotechnology, Inc. Other Non-Current Liabilities
Vir Biotechnology, Inc. (VIR) had Other Non-Current Liabilities of $18.88 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OtherLiabilitiesNoncurrent · last filed 2026-08-05
- 2026-06-30: Other Liabilities, Noncurrent $18.88M.
- 2026-03-31: Other Liabilities, Noncurrent $19.42M.
- 2025-12-31: Other Liabilities, Noncurrent $21.58M.
- 2025-09-30: Other Liabilities, Noncurrent $13.30M.
| Period end | Other Liabilities, Noncurrent | Other Liabilities, Noncurrent as first filed |
|---|---|---|
| 2026-06-30 | $18.88M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $19.42M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $21.58M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $13.30M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $13.03M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $14.81M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $14.58M 10-K · filed 2026-02-23 | |
| 2024-09-30 | $13.89M 10-Q · filed 2024-11-04 | |
| 2024-06-30 | $13.86M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $14.24M 10-Q · filed 2024-05-03 | |
| 2023-12-31 | $15.78M 10-K · filed 2025-02-27 | $14.26M 10-K · filed 2024-02-26 |
| 2023-09-30 | $13.13M 10-Q · filed 2023-11-03 | |
| 2023-06-30 | $12.09M 10-Q · filed 2023-08-04 | |
| 2023-03-31 | $8.23M 10-Q · filed 2023-05-08 | |
| 2022-12-31 | $11.12M 10-K · filed 2024-02-26 | $7.86M 10-K · filed 2023-02-28 |
| 2022-09-30 | $7.17M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $7.60M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $7.75M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $2.54M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $3.82M 10-Q · filed 2021-11-04 | |
| 2021-06-30 | $3.85M 10-Q · filed 2021-08-05 | |
| 2021-03-31 | $3.81M 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $3.85M 10-K · filed 2022-02-28 | |
| 2020-09-30 | $2.98M 10-Q · filed 2020-11-10 | |
| 2020-06-30 | $2.97M 10-Q · filed 2020-08-11 | |
| 2020-03-31 | $2.94M 10-Q · filed 2020-05-12 | |
| 2019-12-31 | $3.57M 10-K · filed 2021-02-25 | |
| 2019-09-30 | $3.03M 10-Q · filed 2019-11-19 | |
| 2018-12-31 | $1.59M 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |